ArticleCureus2025
Pathological Characteristics of Aspirated Thrombi From Coronary Artery Embolism in Patients With Acute Myocardial Infarction.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pathological differences in aspirated thrombi between atherosclerotic causes and coronary artery embolism (CE) in patients with acute myocardial infarction (AMI) remain poorly understood. The purpose of this study was to compare the pathological features of aspirated thrombi between AMI patients with CE and those with atherosclerotic causes (non-CE). Methods: We analyzed coronary thrombi retrieved between 2015 and 2019 from 89 consecutive patients presenting with de novo AMI, of whom four had CE and 85 did not. CE was diagnosed based on angiographic and other diagnostic imaging findings. The samples were stained with hematoxylin and eosin (H&E) and elastica-Masson stain (EM). Immunohistochemistry was performed using specific antibodies against CD34 and CD68 to detect endothelial cells and macrophages, respectively. The aspirated thrombi were assessed for their histopathological characteristics.
resultsAtrial fibrillation (AF) was more frequently documented in patients with CE than in those with non-CE (100% vs. 9%). The erythrocytes and erythrocytes/total thrombus areas were greater. The prevalence of erythrocyte-dominant thrombi was significantly higher in patients with CE than in those with non-CE (4.94 mm² (3.38-7.35 mm²) vs. 0.62 mm² (0.05-2.51 mm²); 55.6% (50.9-57.7%) vs. 12.6% (2.0-36.2%), P = 0.002; and 75% vs. 7%, P = 0.003, respectively). The age of aspirated thrombi was significantly fresher in CE than in the non-CE ("fresh": 75% vs. 18%, "lytic": 25% vs. 28%, and "old": 0% vs. 54%, respectively).
conclusionsThis study suggests that aspirated thrombi derived from patients with AMI due to CE are more erythrocyte-dominant and fresher than those derived from patients with AMI due to atherosclerotic causes. Identifying the etiology of patients with AMI is important because anticoagulation therapy is essential for secondary prevention in patients with CE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.